One of the overexpressed lncRNAs in prostate cancer, *PCGEM1*, is tissue-specific and correlated with high-risk prostate cancer patients, including African-American men^[@R4]^, while a second highly expressed lncRNA, *PRNCR1* (*PCNCR1*), is pervasively transcribed from the *8q24* "gene desert" region in strong association with susceptibility of prostate cancer^[@R5]^. Paired benign prostatic hyperplasia (BPT) and aggressive tumor specimens (Gleason scores 3+3) derived from three individual prostate cancer patients exhibited \>100-fold upregulation of *PRNCR1* and *PCGEM1* expression ([Supplementary Fig. 1a, b](#SD1){ref-type="supplementary-material"}). Native RNA-Immunoprecipitation (RIP) experiments in paired prostate tumor and BPH tissues (Gleason scores 2+3 to 4+3), revealed a specific association of full-length AR with both *PRNCR1* and *PCGEM1* in prostate tumor tissues ([Fig. 1a, b](#F1){ref-type="fig"}; [Supplementary Fig. 1a, c](#SD1){ref-type="supplementary-material"}) compared to minimal interactions with glucocorticoid receptor (GR) ([Supplementary Fig. 1c](#SD1){ref-type="supplementary-material"} and data not shown). In LNCaP cells, DHT treatment induced association of AR with both *PRNCR1* and *PCGEM1* ([Fig. 1c](#F1){ref-type="fig"}), but not with *NEAT2* ([Fig. 1c](#F1){ref-type="fig"}). Antisense oligonucleotides (ASO)-based knock-down of *PRNCR1* abolished both AR-*PRNCR1* and AR-*PCGEM1* interactions while knock-down of *PCGEM1* did not affect the AR-*PRNCR1* interaction ([Fig. 1d](#F1){ref-type="fig"}; [Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}), suggesting the *PRNCR1*-dependent recruitment of *PCGEM1*.

Knock-down of either *PRNCR1* or *PCGEM1* resulted in a significantly decrease in DHT-induced activation of canonical AR target genes while not affecting AR levels ([Supplementary Fig. 2a-c](#SD1){ref-type="supplementary-material"}). Global run-on sequencing (GRO-Seq) confirmed that knock-down of either *PRNCR1* or *PCGEM1* significantly decreased the induction of 617 DHT-upregulated genes (*n*=617, edgeR FDR \< 0.01, and read density RD \> 2) with AR-bound enhancers within 200kb ([Fig. 1e](#F1){ref-type="fig"}), but had no effect on DHT-unresponsive genes located \>200kb away from AR-bound enhancers ([Supplementary Fig. 2d](#SD1){ref-type="supplementary-material"}), verified by randomly extracting sets of 1,000 genes (data not shown).

Using Chromatin Isolation by RNA Purification (ChIRP)^[@R6]^ with biotin-labeled DNA probes (40-60 nt) tiling *PRNCR1* and *PCGEM1* RNAs ([Supplementary Fig. 3a-c](#SD1){ref-type="supplementary-material"}), we identified 2,142 high-confidence *PCGEM1* occupancy sites genome-wide ([Supplementary Fig. 3d, e](#SD1){ref-type="supplementary-material"}) and motif analysis revealed a very significantly enriched AR response element (ARE) DNA motif ([Supplementary Fig. 3f](#SD1){ref-type="supplementary-material"}), revealing that \~82% of *PGCEM1* co-localized with AR-bound sites (−3kb/+3kb relative to the center of *PCGEM1* peak), of which \~70% corresponded to AR bound, H3K4me^[@R1]^-marked enhancers ([Fig. 1f, g](#F1){ref-type="fig"} and [Supplementary Fig. 3g](#SD1){ref-type="supplementary-material"}), independently confirmed by qPCR analyses ([Supplementary Fig. 3h, i](#SD1){ref-type="supplementary-material"}) and ChIRP-Seq using even-numbered and odd-numbered probe sets ([Supplementary Fig. 3j](#SD1){ref-type="supplementary-material"} and data not shown). These data suggest a stoichiometry of *PCGEM1* sufficient to account for the recruitment to AR DNA regulatory binding sites on enhancers. Levels of *PRNCR1* in LNCaP cells are estimated as \~400-600 copies/cell (data not shown). The ability of these lncRNAs to read enhancer-associated histone marks might account for their preferential presence at AR-bound enhancers (*vide infra*).

By imposing a high stringency wash condition, we identified that DOT1L, CARM1, GADD45α, and AR specifically associated with *in vitro*-transcribed biotinylated *PRNCR1* by Mass-spectrometry analysis, while AR, β-Catenin, and Pygopus2 (Pygo2) preferentially associated with *in vitro*-transcribed biotinylated *PCGEM1* ([Supplementary Fig. 4a-c](#SD1){ref-type="supplementary-material"}; [Supplementary Tables 1](#SD3){ref-type="supplementary-material"}-[3](#SD5){ref-type="supplementary-material"}). β-Catenin, CARM1 and GADD45α have been suggested to play important roles in AR signaling^[@R7]^. Knock-down of *AR*, *Dot1L*, β-*catenin*, and *Pygo2* by specific siRNAs impaired DHT-induced activation of AR-target genes, *TMPRSS2*, *PSA*, and *FKBP5* ([Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"}). Mass-spectrometry analysis revealed that the lncRNA-bound AR contains several post-translational modifications, including K631/634 acetylation and K349 methylation ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}; [Supplementary Tables 1](#SD3){ref-type="supplementary-material"}-[3](#SD5){ref-type="supplementary-material"}). Consistent with the proposed importance of acetylation of AR in activation of an AR target gene^[@R8]^, a K631/634R mutation on AR inhibited its interaction with *PRNCR1* and *PCGEM1* ([Fig. 2a](#F2){ref-type="fig"}; [Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}) and DHT-induced expression of AR target genes ([Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}), while overexpression of a AR K631/634Q mutant resulted in enhanced DHT-dependent interactions with *PRNCR1* and *PCGEM* ([Fig. 2a, b](#F2){ref-type="fig"}; [Supplementary Fig. 5c](#SD1){ref-type="supplementary-material"}). These data suggest that *PRNCR1* and *PCGEM1* interact with AR in a K631/634 acetylation- and K349 methylation-dependent manner, respectively.

Because effective AR-*PCGEM1* interaction requires the methylation of AR at K349 ([Fig. 2b](#F2){ref-type="fig"}), we confirmed DOT1L-mediated AR methylation at K349 using *in vitro* methylation assays, finding that a K349R point mutation significantly inhibited AR methylation ([Supplementary 6a;](#SD1){ref-type="supplementary-material"} [Fig. 2c](#F2){ref-type="fig"}). Specific *DOT1L* knock-down impaired the interaction between AR and *PCGEM1*, but not that with *PRNCR1* ([Supplementary Fig. 6b, c](#SD1){ref-type="supplementary-material"}), suggesting that AR K349 methylation, mediated by *PRNCR1*-bound DOT1L, is critical for the recruitment of *PCGEM1* to AR. Indeed, overexpression of an AR K349R mutant significantly reduced DHT-induced gene activation in LNCaP cells ([Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}).

*In vitro* binding studies demonstrated that *PRNCR1* bound to the region aa 549-623 of AR and *PCGEM1* bound to AR N terminal region when methylated at K349 by overexpressing DOT1L ([Fig. 2d, e](#F2){ref-type="fig"}; [Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}). By incubating *in vitro* transcribed *PCGEM1* with nuclear lysate from cells overexpressing Myc-tagged Pygo2 proteins, including full-length, N- or C-terminally truncated proteins, we identified strong interactions between *PCGEM1* and the Pygo2 C-terminus ([Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"}).

To map the sequence motif of *PCGEM1* responsible for AR or Pygo2 binding, we performed modified *in vitro* RNA pulldown followed by dot-blot assay ([Supplementary Fig. 8a](#SD1){ref-type="supplementary-material"}), using two regions of *NEAT2*-bound by unmethylated Pc2 as a control for the CLIP assay^[@R9]^ ([Supplementary Fig. 8b](#SD1){ref-type="supplementary-material"}). Methylated AR bound/protected *PCGEM1* sequence was identified to encompass ^421^GAT...TCC^480^ ([Supplementary Fig. 8c](#SD1){ref-type="supplementary-material"}) with unmethylated AR or the unrelated protein, His-tagged MURF1, not showing specific binding to any region of *PCGEM1* ([Supplementary Fig. 8c](#SD1){ref-type="supplementary-material"}). A sequence motif of *PCGEM1* encompassing ^1201^TGT...ATT^1260^, distinct from the AR binding region, was identified as the Pygo2 binding motif, with deletion of this motif (Δ1191-1270) abolishing Pygo2 binding with no effect on AR binding ([Supplementary Fig. 8c](#SD1){ref-type="supplementary-material"}; [Fig. 2f](#F2){ref-type="fig"}). Similarly, deletion of AR binding site of *PCGEM1* (Δ411-490) abolished AR-*PCGEM1* interaction, with minimal effect on Pygo2-*PCGEM1* interaction ([Fig. 2f](#F2){ref-type="fig"}).

MODified Histone Peptide Array experiments using *in vitro* transcribed biotinylated *PCGEM1* or *PRNCR1* revealed that they selectively recognize H3K4me^[@R1]^ and H4K16^ac^ histone marks indicative of enhancers^[@R10],[@R11]^, respectively ([Supplementary Fig. 9a-c](#SD1){ref-type="supplementary-material"}). Therefore, it is likely that these histone tail associations of *PRNCR1* and *PCGEM1* serve as a functional component of their preferred recruitment to enhancers of AR-regulated transcription units.

*PCGEM1* and *PRNCR1* were highly upregulated in the LNCaP-cds2, and CWR22Rv1 castration-resistant prostate cancer cell line models compared with immortalized "normal" prostate epithelial cell lines, WPE and RWPE, or even LNCaP cells ([Supplementary Fig. 10a, b](#SD1){ref-type="supplementary-material"}). The AR antagonist, bicalutamide (Casodex), reduced the DHT-induced *PSA* expression in LNCaP cells but failed to act as an antagonist in LNCaP-cds2 cells ([Supplementary Fig. 10c](#SD1){ref-type="supplementary-material"}). Transduction of LNCaP-cds2 cells with lentivirus expressing shRNAs against *PRNCR1* or *PCGEM1*, but not a non-specific (*LacZ*) shRNA, significantly reduced the activation of several canonical AR target genes while having no effect on AR expression levels ([Supplementary Fig. 10d-f](#SD1){ref-type="supplementary-material"} and [11a](#SD1){ref-type="supplementary-material"}). Because truncated forms of AR that exhibit ligand-independent transcriptional activation are frequently detected in castration-resistant prostate cancer and may often reflect alterations in AR gene structure, we investigated the potential roles of *PRNCR1* and *PCGEM1* in AR-mediated basal transcription activity in CRPC cells. RT-PCR using primers specific for one AR "splicing" variant, AR-V7^[@R12]^ confirmed the presence of this variant in LNCaP-cds2 cells ([Supplementary Fig. 11b](#SD1){ref-type="supplementary-material"}). Western blot analysis using N-terminal AR-specific antibody (441), revealed that the AR-V7 variant (\~75kDa) represents \~1-2% of total AR in LNCaP-cds2 cells, although it is the predominant form in CWR22Rv1 cells ([Supplementary Fig. 10g](#SD1){ref-type="supplementary-material"}). Because overexpression of truncated AR can constitutively activate androgen-responsive genes in the absence of ligand^[@R12]^, we transfected LNCaP cells with AR Q641X mutant, with activation of canonical androgen-responsive genes, including *TMPRSS2*, *PSA*, *KLK2*, *FKBP5*, and *NKX3-1* in the absence of added androgen ([Fig. 3a](#F3){ref-type="fig"}; [Supplementary Fig. 12a, b](#SD1){ref-type="supplementary-material"}). This constitutive effect of AR Q641X was highly reduced upon knock-down of either *PRNCR1* or *PCGEM1* ([Fig. 3a](#F3){ref-type="fig"}). RIP assay in CWR22Rv1 cells demonstrated that both *PRNCR1* and *PCGEM1* associated constitutively with truncated AR (AR-V7) with or without ligand ([Fig. 3b](#F3){ref-type="fig"}). By immunoblotting the AR-V7 immunoprecipitates with N-terminal AR-specific antibody (441), we did not observe any residual pull-down indicative of interaction between full length and truncated AR ([Fig. 3b](#F3){ref-type="fig"}, right panel), arguing against an indirect association of *PRNCR1* and *PCGEM1* with truncated AR consequent to hetrodimerization with full length AR. Using an antibody specific for the C-terminal ligand binding domain of AR (C-19) to selectively recognize full length AR, we observed interactions between these lncRNAs and full length AR in the absence of added ligand ([Fig. 3b](#F3){ref-type="fig"}), possibly due to the relative higher level of basal acetylation and methylation of full-length AR in CWR22Rv1 cells ([Supplementary Fig. 12c](#SD1){ref-type="supplementary-material"}).

To study the biological roles of *PRNCR1* or *PCGEM1*, we generated stable cell lines derived from CWR22Rv1 harboring Doxycycline (Dox)-induced shRNA against *LacZ*, *PRNCR1* or *PCGEM1* ([Supplementary Fig. 13a](#SD1){ref-type="supplementary-material"}). Dox-induced either *PCGEM1* or *PRNCR1* knock-down significantly reduced the expression of canonical AR target genes, with no noticeable effect on AR expression level ([Supplementary Fig. 11a, 13b](#SD1){ref-type="supplementary-material"}). Dox-induced knock-down of either *PRNCR1* or *PCGEM1* also inhibited the growth of CWR22Rv1 cells comparable to the effect of AR knock-down^[@R13]^, without affecting AR expression levels ([Fig. 3c](#F3){ref-type="fig"}; [Supplementary Fig. 11a](#SD1){ref-type="supplementary-material"} and [13c](#SD1){ref-type="supplementary-material"}). Remarkably, conditional shRNA-mediated inhibition of either *PRNCR1* or *PCGEM1* robustly inhibited *in vivo* tumor growth in a CWR22Rv1 prostate cancer xenograft mice model ([Fig. 3d](#F3){ref-type="fig"}), indicative of an lncRNA-dependent regulatory network that critically regulates growth of castration-resistant prostate cancer cells *in vivo*.

While knock-down of either *PRNCR1* or *PCGEM1* did not affect the recruitment of AR on *PSA* and *KLK2* enhancers ([Supplementary Fig. 14a, b](#SD1){ref-type="supplementary-material"}, left panels), knock-down of *PCGEM1* inhibited SMC1 recruitment on *PSA* and *KLK2* promoters, with only minimal effects on SMC1 levels on enhancers ([Supplementary Fig. 14a, b](#SD1){ref-type="supplementary-material"}, right panels), consistent with proposed Cohesin-dependent^[@R14]^ formation of chromatin loops between enhancers and promoters. We further demonstrated ligand-induced enhancer: promoter interactions in the *PSA* transcription unit by ChIP-3C assay^[@R15]^ and found that these interactions were impaired by depletion of either *PRNCR1* or *PCGEM1* ([Fig. 4a](#F4){ref-type="fig"}; [Supplementary Fig. 14c](#SD1){ref-type="supplementary-material"}).

The ability of Pygo2, associated with *PCGEM1* ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}), to recognize a canonical promoter histone mark^[@R16]^, H3K4me^[@R3]^, raised the possibility that Pygo2 might be involved, at least quantitatively, in enhancer: promoter looping. ChIP assays revealed that Pygo2 was efficiently recruited to enhancer and promoter regions of the *PSA*, *KLK2* and *TMPRSS2* transcription units in a DHT-dependent manner, exhibiting relatively higher and earlier association with the enhancer regions ([Fig. 4b](#F4){ref-type="fig"}; [Supplementary Fig. 15a](#SD1){ref-type="supplementary-material"}). Knock-down of either *PRNCR1* or *PCGEM1* in LNCaP cells inhibited Pygo2 recruitment to AR-dependent enhancers/promoters ([Fig. 4c](#F4){ref-type="fig"}; [Supplementary Fig. 15b](#SD1){ref-type="supplementary-material"}). On knock-down of *Pygo2* , AR and SMC1 failed to effectively associate with the *PSA*, *KLK2* or *TMPRSS2* promoters despite unperturbed DHT-dependent AR or SMC1 recruitment to their enhancers ([Supplementary 16a-d](#SD1){ref-type="supplementary-material"}) and DHT-induced enhancer: promoter looping in the *PSA* transcription unit was inhibited ([Fig. 4d](#F4){ref-type="fig"}). GRO-Seq analysis revealed a broad inhibition of AR-dependent transcriptional program under the condition of *Pygo2* knock-down (*n*=290, edgeR FDR \< 0.01), which did not affect AR expression ([Fig. 4e](#F4){ref-type="fig"}; [Supplementary Fig. 16a](#SD1){ref-type="supplementary-material"}).

Depleting *PRNCR1* or *PCGEM1* from LNCaP-cds2 cells also inhibited enhancer: promoter looping in *FASN* and *NDRG1* ([Supplementary Fig. 17a-d](#SD1){ref-type="supplementary-material"}; [Fig. 4f](#F4){ref-type="fig"}), previously shown to be activated following FoxA1 knock-down in LNCaP cells^[@R17]^. Again, knock-down of either *PRNCR1* or *PCGEM1* had no effect on recruitment of AR to enhancer regions of the *FASN* and *NDRG1* transcription units or on *Pygo2* expression levels ([Supplementary Figs. 16a, 17e](#SD1){ref-type="supplementary-material"}).

To address whether the Pygo2 PHD domain might itself be instrumental for its function in mediating chromatin looping, we first depleted Pygo2 by shRNA followed by overexpression in LNCaP-cds2 cells of either shRNA-resistant wild-type Pygo2^[@R18]^ or a W352A mutant defective for H3K4me^[@R3]^ recognition^[@R16]^. In 3C assays, knock-down of Pygo2 reduced *FASN* enhancer: promoter interactions, which could be rescued by overexpression of wild-type, but not W352A, Pygo2 ([Supplementary Fig. 18a, 19a](#SD1){ref-type="supplementary-material"}), even though there was equal recruitment of wild-type Pygo2 or the W352A mutant to enhancers, and no altered promoter H3K4me^[@R3]^ levels ([Supplementary Fig. 18b-d](#SD1){ref-type="supplementary-material"}). Knock-down of *Pygo2* curtailed the expression of canonical of AR target genes *TMPRSS2*, *KLK2*, *PSA*, *FKBP5*, and *NKX3-1*, and overexpression of wild-type, but not W352A, Pygo2 was able to robustly rescue the induction of these genes ([Supplementary Fig. 19b](#SD1){ref-type="supplementary-material"}). These data suggest that Pygo2 exerts a quantitatively-important role in DHT-dependent enhancer: promoter interactions and coding target gene activation. For 220 AR-regulated coding gene promoters under regulation of an enhancer exhibiting ligand-dependent recruitment of Pygo2 also exhibiting recruitment to the coding gene promoter by ChIP-seq, we did not observe ligand-induced increase in the next adjacent, non-AR-regulated transcription unit (\~204 promoters) ([Supplementary Fig. 19c](#SD1){ref-type="supplementary-material"}), indicating that the H3K4me^[@R3]^ mark cannot alone be sufficient to effectively recruit Pygo2, suggesting a role of other similarly-modified proteins in prostate cancer cell gene activation events.

In the present study, we have found a mechanistic link between prostate cancer-upregulated lncRNAs and AR transcriptional activity, revealing the biological importance of the lncRNAs, *PRNCR1* and *PCGEM1*, in licensing C-terminally truncated, as well as full length, AR-dependent gene activation events in prostate cancer cells ([Supplementary Fig. 19d](#SD1){ref-type="supplementary-material"}). Considering the regulatory potential of enhancer RNAs (eRNAs) identified in recent studies^[@R19],[@R20]^, lncRNAs may also be part of a broad transcription regulatory network.

Methods {#S2}
=======

Tissue Samples and Processing {#S3}
-----------------------------

Experiments using paired benign prostatic hyperplasia (BPT) and tumor (T) were performed from unidentified individual prostate cancer patients, which were obtained from Dr. Ralph W. deVere White, UC Davis Comprehensive Cancer Center. The informed consent was obtained from all subjects. The tissue samples used in manuscript were received as the de-identified samples without any PHI attached. The Gleason score or tumor/BPH status was considered pathological information, not patient information. We did not know the names or birth dates. The tissues were homogenized by Precellys®24 tissue homogenizer followed by downstream assays.

Cell Culture and Transfection {#S4}
-----------------------------

Prostate cancer LNCaP cells were obtained from ATCC and cultured in RPMI1640 containing 10% (vol/vol) FBS. The benign immortalized prostate cell line RWPE, WPE and the castration-resistant prostate cancer cell lines LNCaP-cds1, LNCaP-cds2, CWR22Rv1 were kindly provided by Dr. Christopher Evans (Department of Urology, University of California Davis). RWPE and WEP cells were grown in KGM media and bulletkit from Lonza supplemented with L-Glutamine. CWR22Rv1, LNCaP-cds1 and LNCaP-cds2 cells were grown in RPMI1640 media containing 5% final volume of Charcoal Stripped Serum. LNCaP cells were grown to 30-50% confluence and siRNA/ASO transfections were carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Transfection of LNCaP cells with DNA plasmids was performed using Amaxa™ Nucleofector™ kit R from Lonza. shRNAs specific for *LacZ*, *PRNCR1*, *PCGEM1* or *AR* were delivered, by lentiviral transduction, to LNCaP-cds2 and CWR22Rv1 cells.

Cloning Procedures {#S5}
------------------

The full-length AR expression vector has been previously described^[@R17]^. Human *PCGEM1* (14-1556) and *PRNCR1* fragments (1-3240, 3156-6428, 6331-9670 and 9531-12710) were amplified from cDNAs generated from LNCaP cells and cloned into pSTBlue-1 vector (Novagen) for *in vitro* transcription assay. *PCGEM1* gene sequence with 411-490 and 1191-1270 deletion were synthesized by GeneScript Inc. and cloned into pcDNA3.1 vector (Invitrogen). Lentiviral vector pLKO.1 containing the shRNA against scrambled sequence, Pygo2 and pHIV vector containing RNAi-resistant Pygo2 cDNA were obtained from Dr. Xing Dai (Department of Biological Chemistry, University of California at Irvine)^[@R18]^. A 4.8 kb genomic sequence upstream of *PSA* promoter was amplified from LNCaP cells and subcloned into pSTBlue-1 vector (Novagen). Bacterial expression vectors for AR and K349R mutant were constructed by subcloning the gene sequences into pET-28a backbone (Novagen). Nuclear expression vectors for AR~2-920~, AR~2-548~, AR~549-920~, AR~2-623~, AR~549-623~, AR~624-666~, AR~667-920~ and Pygo2~2-406~, Pygo2~2-266~, Pygo2~267-406~ were constructed by subcloning the cDNA sequences into pCMV/myc/nuc backbone (Invitrogen). The expression vector of FLAG-DOT1L was kindly provided by Dr. Yi Zhang's laboratory. All mutants were generated using QuikChange™ Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). Detailed oligonucleotide sequences were listed in **Oligonucleotide Sequences and Primers** section.

Antisense DNA Oligonucleotide, siRNA and Lentiviral shRNA {#S6}
---------------------------------------------------------

2′-O-methyl phosphor-othioate oligonucleotides were designed and synthesized by Integrated DNA Technologies, Inc. Commercially available FlexiTube siRNA targeting AR (SI02757258) and CARM1 (SI02663815) from Qiagen, ON-TARGETplus SMARTpool siRNA targeting DOT1L (L-014900-01-0005) and GADD45α (L-003893-00-0005) from Dharmacon, MISSION® siRNA targeting β-Catenin (SASI_Hs01_00117958), Pygopus2 (SASI_Hs01_00059018) from Sigma-Aldrich were used in this study. The knockdown efficiency and specificity of all siRNAs were validated either by vendors or ourselves ([Supplementary Fig. 6b, 16a](#SD1){ref-type="supplementary-material"}). Oligonucleotides for shRNA targeting *PRNCR1*, *PCGEM1* and *AR* were designed at<http://biosettia.com/support/shrna-designer> and cloned into pLV-H1TetO-GFP-Puro vector according to manufacturer's instructions (Biosettia). We tested the efficacy and specificity of 3 ASOs (see [Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}) and 2 shRNAs (see [Supplementary Fig. 10d](#SD1){ref-type="supplementary-material"}) in LNCaP and LNCa-cds2 cells, respectively, for both *PRNCR1* and *PCGEM1*. For functional assays, the specific ASO/shRNA giving the best knockdown efficiency was used. Detailed ASO/shRNA sequences were listed in **Oligonucleotide Sequences and Primers** section.

Antibodies {#S7}
----------

Specific antibodies were purchased from the following commercial sources: anti-AR (N-20), anti-AR (C-19), anti-AR (441), anti-GR (E-20), anti-β-Catenin (D-10), and anti-GAPDH (6C5) from Santa Cruz Biotechnology; anti-CARM1 (4438), anti-GADD45α (3518) and anti-pan acetylated-lysine (\#9441) from Cell Signaling Technology; anti-FLAG® M2, anti-γ-Tubulin (T5326) and anti-Pygo2 from Sigma-Aldrich Prestige Antibodies®; anti-Pygo2 (GTX119726) from GeneTex Inc.; Anti-DOT1L (39954) and anti-Myc tag (clone 4E12) from Active Motif; anti-SMC1 (A300-055A) from Bethyl Laboratories Inc.; anti-pan methylated lysine (7315) from Abcam and anti-AR-V7 from Precision Antibody^™^.

### Protein Recombination and Purification {#S8}

Recombinant His-AR proteins were expressed in *E.coli* strain BL21-CodonPlus® (DE3)-RIPL (Agilent Technologies) and purified using TALON® Metal Affinity Resin (Clontech). Recombinant Histone H3 was purchased from Active Motif. Human DOT1L (amino acids 2-416) was obtained from Sigma-Aldrich. Human Pygo2 was purchased from BioClone Inc. His-tagged MURF1 was purchased from BostonBiochem®.

RNA Immunoprecipitation (RIP) {#S9}
-----------------------------

RIP was performed in native conditions as described^[@R21]^. Briefly, 1×10^7^ LNCaP cell nuclei were pelleted and lysed in 1mL ice-cold Polysomal Lysis Buffer (100mM KCl, 5mM MgCl~2~, 10mM HEPES \[pH 7.0\], 0.5% NP-40, 1mM DTT) supplemented with Anti-RNase, Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail, Panobinostat, and Methylstat. The lysate were passed through a 27.5 gauge needle 4 times to promote nuclear lysis. Turbo™ DNase (400 U) was then added to the lysate and incubated on ice for 30 min. The cell lysate was diluted in the NT2 buffer (50mM Tris-HCl \[pH 7.4\], 150mM NaCl, 1mM MgCl~2~, 0.05% NP-40) and 50 ul of the supernatant was saved as input for PCR analysis. 500 ul of the supernatant was incubated with 4 μg of AR (441) antibodies-IgG magnetic beads (pre-blocked by 1×PBS+5 mg/ml BSA) at 4 °C overnight. The RNA/antibody complex was washed four times (1 ml wash, 5 minutes each) by NT2 buffer supplemented with Anti-RNase, Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail, Panobinostat and Methylstat. The RNA was extracted using Acid-Phenol: Chloroform, pH 4.5 (with IAA, 125:24:1) (Invitrogen) according to the manufacturer's protocol and subjected to RT-qPCR analysis.

*Ch*romatin *I*solation by *R*NA *P*urification (ChIRP) {#S10}
-------------------------------------------------------

ChIRP was performed as described^[@R6]^ with minor modifications. Briefly, 60-mer antisense DNA probes targeting *PRNCR1* and *PCGEM1* full-length sequences were designed at <http://www.singlemoleculefish.com/designer.html>. A set of probes targeting *LacZ* RNA was also designed as the negative control. All probes were biotinylated using Label I® Nucleic Acid Biotin Labeling Kit from Mirus Biotechnology. LNCaP cells were fixed with 1% formaldehyde for 10 min at room temperature. Crosslinking was then quenched with 125mM glycine for 5 min. The chromatin preparation, hybridization/elution, deep sequencing steps were essentially performed as described^[@R4]^ except that wash was conducted at 50 °C and 65°C. The image analysis and base calling were performed using Illumina's computational analysis pipeline. The sequencing reads were aligned to hg18 human genome by using Bowtie2^[@R22]^ and only 1 read/position was kept for downstream analyses. Peak finding was performed by using HOMER suite^[@R23]^ and the peaks within 1kb from each other were merged. Peak intersection was computed by using intersectBed in BedTools^[@R24]^, after extending the peaks with 1kb. In order to call reliable peaks, we have excluded from analysis the peaks that overlapped the satellite repeats or *LacZ* ChIRP peaks. The annotation of the peaks on the human genome and the tag density profiles were computed in HOMER, and the display of the heatmap were carried in MeV^[@R25]^. Sequenced motif enrichment analysis was carried in HOMER. For ChIP-Seq data (AR and H3K4me^[@R1]^), peak finding was performed by using HOMER or SICER^[@R26]^.

Data Processing Procedure for Overlapping ChIP-Seq and ChIRP-Seq {#S11}
----------------------------------------------------------------

We used the standard ChIP-Seq peak finding tools in the processing of ChIRP-Seq data. We chose HOMER software suite (<http://biowhat.ucsd.edu>) for the analysis of both AR ChIP-Seq and *PCGEM1* ChIRP-Seq data, using the same program routine (i.e. findPeaks command) and the same default parameters that calls only the robust peaks (these parameters are outlined below): 1) fold enrichment over input tag count, default: 4.0; 2) poisson p-value threshold relative to input tag count, default: 0.0001; 3) fold enrichment over local tag count, default: 4.0; 4) poisson p-value threshold relative to local tag count, default: 0.0001; 5) fdr \<\#\> false discovery rate, default = 0.001; 6) size of region used for local filtering = 10000; 7) fold over local region required = 4.00. Peak finding procedure: 1) typically, the tag distribution along the genome could be modeled by a Poisson distribution and the peak finding algorithm slides windows of fixed size across the genome to find candidate peaks with a significant tag enrichment (Poisson distribution p-value default 10-4 to 10-5); 2) we use very strict parameters in HOMER to call a peak: a very low FDR (i.e. 0.001), and a high fold enrichment over input tag count (i.e. 4). By default, HOMER also requires the tag density at peaks to be 4-fold greater than in the surrounding 10 kb region. Therefore, we ensure that only the sharp peaks with low local background are called and considered for downstream analyses. Both ChIP-seq and ChIRP-seq data were processed precisely in the same way using the same default settings of HOMER.

For the analysis of overlapping between ChIP-Seq and ChIRP-Seq data, we used the following samples: *PCGEM1*ChIRP-Seq (−DHT), *PCGEM1* ChIRP-Seq (+DHT), and AR ChIP-Seq (at a higher sequencing depth). The heatmaps were generated in 2 steps: 1) we used HOMER and the command \[(annotatePeaks.pl \<peak file\> \<genome\> −size \<\#\> −hist \<\#\> −ghist) that specifies the list of peaks (\<peak file\>), and the tag density in a region that covers \<size\> kb around the peak center; the tag density is specified in a bin size that is specified by the parameter \<hist\>)\] to generate a matrix of tag densities across the samples, for each peak. Typically the tag densities are normalized to 10 mil reads for each sample; 2) we used MeV package (<http://www.tm4.org/mev/>) to display the heatmap and to color code it on a scale from 0 to 2: a difference in the colors from 2 (red) to 0 (green) may reflect a fold enrichment over local tag count higher than 4 (4 is typically the default value, used for peak finding, as we described above).

GRO-Seq {#S12}
-------

The image analysis and base calling were performed by using Illumina's standard computational analysis pipeline. Bowtie2^[@R22]^ was used to align the sequencing reads to hg18 human genome; when multiple reads aligned to the same genomic position, only 1 read/position was kept for downstream analyses. We have used RefSeq annotations in order to estimate the gene expression level by counting the sequencing reads over the gene body (from 400bp downstream of TSS to TTS) on the sense strand with respect to the gene transcription, by using intersectBed in BedTools^[@R24]^. In order to call statistically significant differentially expressed genes, we have used edgeR^[@R27]^ and a FDR \< 0.01. Additional criteria, including read density (normalized number of reads/kb) were imposed in order to filter the differentially expressed genes. Wilcoxon tests for sample comparisons were computed in R.

Chromatin immunoprecipitation (ChIP) assay, ChIP-Seq and ChIP-3C assay {#S13}
----------------------------------------------------------------------

ChIP assays and ChIP-Seq was performed as described^[@R28]^. ChIP-3C assays were performed as described^[@R15]^ with minor modifications. Briefly, LNCaP cells were cross-linked with 1% formaldehyde for 10 min followed by incubation with 125mM glycine for 5 min. The cross-linked chromatin was sonicated and digested with restriction enzyme BstYI (New England Lab) followed by immunoprecipitated with specific antibody coupled to Protein A Dynabeads® (Invitrogen). The beads bound chromatin was ligated with T4 DNA ligase (Promega), eluted and reverse-cross-linked. The ChIP-3C material was purified by QIAquick Gel Extraction Kit (Qiagen) and subjected to PCR analysis with sets of primers as described^[@R15]^.

3C Assay {#S14}
--------

LNCaP-cds2 cells were cross-linked with 1% formaldehyde for 10 min at room temperature and processed according to the procedures as described^[@R17]^ with minor modification. Briefly, BAC clones (Empire Genomics) for *FASN* (RP11-1033I, RP11-1033J9) and *NDRG1* (RP11-671M3, RP11-125I19) loci were used to generate control templates for the positive controls. 15 μg of the BAC clone for each locus were mixed and digested with 300 units of corresponding restriction enzyme overnight at 37^o^C. DNA fragments were extracted and ligated with T4 DNA ligase at a DNA concentration of 300 ng/μl. The primers for the fragments on the *FASN* and *NDRG1* loci were used as previously described^[@R17]^.

*In Vitro* RNA pulldown Coupled with Dot-Blot Assay {#S15}
---------------------------------------------------

*In vitro* transcribed biotinylated RNA was formed secondary structure as described^[@R29]^ and incubated with recombinant His-tagged or GST-tagged proteins in gel shift protein binding buffer (Promega) on ice for 1 hour. The reactions were ultraviolet (UV) irradiated (150 mJ/cm^2^) to crosslink RNA-protein complexes. After UV irradiation, the RNA was partially digested by RNase I (Ambion) at 1:50 and 1: 500 dilutions for 5 min, allowing a small fragment to remain attached to protein. RNA-protein complexes of interest were then partially purified by His tag or GST tag magnetic beads and the purified RNA-protein complexes were treated with proteinase K, which removes protein but leaves intact RNAs. The recovered RNAs were hybridized to BrightStar®-Plus Positively Charged Nylon Membrane spotted with 60-mer antisense DNA oligonucleotides tiling along the indicated lncRNA sequence at 37 °C overnight. The anti-sense oligonucleotides corresponding to the indicated lncRNAs were spotted on membrane as following order (left to right in each row): A1 is corresponding to the oligonucleotide sequence nt 1-60 of indicated lncRNA, A2 is corresponding to oligonucleotide sequence nt 61-120 of indicated lncRNA and so on till the end of the lncRNA sequences. The hybridized membrane was washed as described at sequential 37°C, 50 °C and 65°C. The protein-bound RNA sequence was visualized by detection of Streptavidin-HRP signals. The positions and sequences of antisense DNA oligonucleotides tiling along *PCGEM1* is available upon request.

*In Vitro* Methylation Assay {#S16}
----------------------------

*In vitro* methylation assays were conducted in a total volume of 30 μl using 2 μg of substrate, and 1 μg of recombinant GST-DOT1L in methylation buffer (50 mM HEPES \[pH 8.0\], 0.01% (v/v) NP-40, 10 mM NaCl, 1 mM DTT and 1 mM PMSF) supplemented with either 40 μM S-Adenosyl-methionine (SAM, Sigma-Aldrich; for nonradioactive methylation) or 300 nM S-Adenosyl-L-\[methyl-\[^3^H\]methionine (\[^3^H\]-SAM, Perkin Elmer; 0.55 μCi *per* reaction for radioactive methylation). Reactions were carried out at 37°C for 3 hours and the reactions were separation on a 4-12% SDS-PAGE gel. The resulting protein bands were visualized by Coomassie blue staining, immunoblotting or autoradiography using EN3HANCE™ spray (Pelkin Elmer). Purification of methylated protein was carried out as described^[@R9]^.

Cell Lysis, Protein Immunoprecipitation, and Immunoblotting {#S17}
-----------------------------------------------------------

Cells were homogenized in 1×RIPA buffer with protease inhibitor and Anti-RNase (Invitrogen). Lysates were cleared by centrifugation at 13,000 rpm for 15 min at 4°C. The protein concentration of the extracts was determined by Bradford assay (Bio-Rad). Immunoprecipitation experiments and immunoblotting analyses were performed as described in previous studies^[@R9]^. The blotting signals were detected using SuperSignal West Dura Extended Duration Substrate (Pierce).

Lentivirus Packaging and Transduction {#S18}
-------------------------------------

Production of Lentiviral shRNA stocks were performed in 293LTV cell line according to manufacturer's instruction (Cell Biolabs). The lentivirus was further purified and concentrated by ViraBind™ Lentivirus Concentration and Purification Kit (Cell Biolabs). LNCaP-cds2 and CWR22Rv1 cells were transduced using ViraDuctin™ Lentivirus Transduction Kit (Cell Biolabs) and purified with 0.6 and 0.4 μg/ml puromycin, respectively. To establish stable cell line expressing shRNA against *LacZ*, *PRNCR1*, *PCGEM1* or *AR*, CWR22Rv1 cells were transduced as described above and stable transduced clones were generated following selection with 0.4 μg/ml puromycin. Single cell clones were then isolated by three rounds of single cell dilution, and the efficiency of Doxycycline-induced target gene knockdown was screened by RT- qPCR with 24 individual clones for each target gene (see [Supplementary Fig. 13a](#SD1){ref-type="supplementary-material"}).

RNA Pulldown Assay and Mass Spectrometric Analysis {#S19}
--------------------------------------------------

RNA pulldown assay was performed as previously described^[@R9]^ with minor modifications. Biotin-labeled *PCGEM1* RNA (14-1556) and *PRNCR1* RNA fragments (1-3240, 3156-6428, 6331-9670 and 9531-12710) were *in vitro* transcribed with the Biotin RNA Labeling Mix (Roche) and T7 or SP6 RNA polymerase (Promega) and purified with RNeasy® Mini Kit (QIAGEN). RNAs were incubated with nuclear extract from LNCaP cells in the presence of anti-RNase, Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail, Panobinostat, and Methylstat. Proteins pulled down by biotinylated *PRNCR1* and *PCGEM1* were first eluted, denatured, reduced, alkylated and then digested with immobilized trypsin (Promega). The digested peptides were batch purified on a reversed-phase ZipTip® (Millipore), and resulting peptide pools were then subjected to mass spectrometric analysis at UCSD Biomolecular and Proteomics Mass Spectrometry Facility. Data were analyzed using ProteinPilot™ software (Applied Biosystems).

Modified Histone Peptide Array {#S20}
------------------------------

The interaction between *in vitro* transcribed *PRNCR1* and *PCGEM1* with Histone was analyzed by MODified™ Histone Peptide Array (Active Motif) according to manufacturer's instruction. The specificity of interactions was quantified by Array Analyses Software (Active Motif).

Histone Peptide Pulldown Assay {#S21}
------------------------------

Histone peptide pulldown assays were performed using SensoLyte® Methylated Histone H3 kit from AnaSpec. Briefly, 1μg of recombinant Pygo2 protein was incubated with 1μg of biotinylated histone H3 peptides (unmodified, K4me^1^, K4me^2^, or K4me^3^) in the presence of yeast tRNA or *in vitro* transcribed *PCGEM1* in binding buffer (50 mM Tris-HCl, pH7.5, 150 mM NaCl, 0.05% NP-40) for 2hrs at 4°C with rotation. After 1hr incubation with streptavidin magnetic beads and extensive washing, the bound protein was analyzed by SDS-gel electrophoresis and western blotting with anti-Pygo2 antibodies. For this assay, *PCGEM1* was *in vitro* transcribed using unlabeled UTP.

Cell Proliferation Assay {#S22}
------------------------

Cell proliferation assay was performed using CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) (Promega). Briefly, cells were distributed in 96-well plate with 100 μl media each. After removing media and rinsed once by PBS, cells were supplied with 100 μl PBS mixed by 4 μl MTS reagent, followed by 1hr incubation at 37°C 5% CO2 incubator. After incubation, 490nm absorption of each well was measured by light absorbance reader. Every group has 6 replicates.

Xenografts and Animals {#S23}
----------------------

CWR22Rv1 stable cell lines with Doxycycline-inducible shRNA against *LacZ*, *PRNCR1* or *PCGEM1* were injected into male athymic Nu/Nu mice, 4-5 weeks old. Mice arrived in our facility were randomly put into cages with four mice each. They were implanted with respective tumor cells in the unit of cages. Three million of cells were suspended with matrigel in the ratio of 2:1 for subcutaneous injection. The experiment was set up to use eight animals *per* group to detect a 2-fold increase in tumor size with power of 80% and at the significance level of 0.05 by a two-sided test for significant studies. In these experiments, the tumor take rate was often about 50%, so we often ended up with about 4 animals *per* group, with or without doxycycline treatment. Tumor progression was monitored by caliper measurement twice a week and the tumor volume was calculated according to the equation, *v*=length × width2 ×1/2. When the tumor size reached between 150 -- 200 mm3, animals were randomly distributed to groups receiving 1 mg/ml of doxycycline water or regular water with continuous tumor monitor until tumor burden exceeded the limit of IACUC humane endpoints (less than 20 mm in one dimension), for 3 to 4 weeks. The investigators were blinded to the group allocation during the experiment and/or when assessing the outcome. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animals were housed in the UC Davis Medical Center Animal Facility (Sacramento, CA) under pathogen-free conditions; protocol approved by the Institutional Animal Care and Use Committee.

RNA isolation and qRT--PCR {#S24}
--------------------------

Total RNA was isolated from cells using RNeasy Plus Mini Kit (Qiagen) following the manufacturer's protocol. First-strand cDNA synthesis from total RNA was carried out using iScript™ cDNA Synthesis Kit (Bio-Rad). Resulting cDNA was then analyzed by qPCR using SsoAdvanced™ SYBR® Green Supermix (Bio-Rad) on Stratagene Mx3000 or CFX Connect™ Real-Time PCR Detection System. Primers are specific for genes tested and their sequences are listed in **Oligonucleotide Sequences and Primers** section. All qPCRs were repeated at least three times.

Oligonucleotide Sequences (5′-3′) and Primers (forward and reverse) {#S25}
-------------------------------------------------------------------

### Antisense Oligonucleotide {#S26}

Scrambled (mA\*mA\*mG\* mC\*mG\*C\* G\*C\*A\* C\*C\*A\* G\*C\*G\* mC\*mC\*mU\* mC\*mC)^[@R30]^, *PRNCR1* \#1 (mC\*mC\*mC\* mU\*mC\*C\* T\*C\*C\* C\*T\*C\* T\*C\*T\* mC\*mU\*mU\* mG\*mC), *PRNCR1* \#2 (mA\*mC\*mU\* mC\*mU\*C\* C\*T\*T\* C\*T\*C\* C\*A\*C\* mC\*mU\*mC\* mC\*mA), *PRNCR1* \#3 (mA\*mC\*mU\* mC\*mC\*C\* A\*C\*A\* C\*C\*A\* C\*C\*A\* mC\*mC\*mA\* mC\*mC), *PCGEM1* \#1 (mU\*mU\*mC\* mC\*mC\*T\* C\*T\*G\* C\*T\*T\* G\*C\*C\* mU\*mG\*mU\* mU\*mG), *PCGEM1* \#2 (mG\*mC\*mU\* mU\*mU\*A\* C\*C\*C\* T\*T\*A\* G\*T\*C\* mC\*mU\*mC\* mC\*mA), and *PCGEM1* \#3 (mA\*mG\*mU\* mC\*mC\*T\* C\*C\*A\* C\*G\*T\* G\*C\*C\* mU\*mA\*mC\* mC\*mC).

### shRNA {#S27}

*Lac Z* (AAA AGC AGT TAT CTG GAA GAT CAG GTT GGA TCC AAC CTG ATC TTC CAG ATA ACT GC) (Bioseitta); *PRNCR1* \#1 (AAA ACA GTT TGA TTA GGG AGG CAC ATT TAT TGG ATC CAA TAA ATG TGC CTC CCT AAT CAA ACT G); *PRNCR1* \#2 (AAA AAA GGA AGG ACT TTC CAG CAC CTT AAT TGG ATC CAA TTA AGG TGC TGG AAA GTC CTT CCT T); *PCGEM1* \#1 (AAA ACC TTT GCA GAG AGC ATG CTT TCC TAT TGG ATC CAA TAG GAA AGC ATG CTC TCT GCA AAG G); *PCGEM1* \#2 (AAA AAC AAC CTT TGC AGA GAG CAT GCT TTT TGG ATC CAA AAA GCA TGC TCT CTG CAA AGG TTG T); and *AR* (AAA AGG TTC TCT GCT AGA CGA CAT TGG ATC CAA TGT CGT CTA GCA GAG AAC C)^[@R13]^.

### qPCR Primer for Gene Expression and RIP {#S28}

*Actin* (GCT CGT CGT CGA CAA CGG CTC and CAA ACA TGA TCT GGG TCA TCT); *PRNCR1* (CCA GAT TCC AAG GGC TGA TA and GAT GTT TGG AGG CAT CTG GT); *PCGEM1* (GGT GCC TTT GCC AAT GTT AT and AGC ATG CTC TCT GCA AAG GT); *NEAT2* (TGG GGG AGT TTC GTA CTG AG and TCT CCA GGA CTT GGC AGT CT); *TMPRSS2* (CTG GTG GCT GAT AGG GGA T and GTC TGC CCT CAT TTG TCG AT); *KLK2* (AGC CTG CCA AGA TCA CAG AT and GCA AGA ACT CCT CTG GTT CG); *PSA* (GAT GCT GTG AAG GTC ATG GA and TGG AGG TCC ACA CAC TGA AG); *FKBP5* (TCC CTC GAA TGC AAC TCT CT and GCC ACA TCT CTG CAG TCA AA); *NKX3-1* (GCC AAG AAC CTC AAG CTC AC and AGA AGG CCT CCT CTT TCA GG); *PGC-1* (GAG TTC CTG AGG ACC CAC AA and AGG AAG TTC TGG GGT GGA GT); *FASN* (AGG ATC ACAG GGA CAA CCT G and ACT CCA CAG GTG GGA ACA AG); and *NDRG1* (ACC TGC TAC AAC CCC CTC TT and TGA TCC ATG GAG GGG TAC AT).

### qPCR Primer for ChIRP and ChIP {#S29}

*PSA* enhancer (TGG GAC AAC TTG CAA ACC TG and CCA GAG TAG GTC TGT TTT CAA TCC A); *PSA* middle region (CAG TGG CCA TGA GTT TTG TTT G and AAC CAA TCC AAC TGC ATT ATA CAC A); *PSA* promoter (CCT AGA TGA AGT CTC CAT GAG CTA CA and GGG AGG GAG AGC TAG CAC TTG); *KLK2* enhancer (GTT GAA AGC AGA CCT ACT CTG GA and GCA TAT TTG TAC AGC AGA TAG CC); *KLK2* middle region (ATC TCA AGG ACT TCT GGG TGG A and TGG GTA GTC CCT GTT ACA AGA T); *KLK2* promoter (GGG AAT GCC TCC AGA CTG ATC and CTT GCC CTG TTG GCA CCT AGA); *TMPRSS2* enhancer (TGG TCC TGG ATG ATA AAA AAA GTT T and GAC ATA CGC CCC ACA ACA GA); *TMPRSS2* middle region (CCA GAA GAA TAC AAT GAT TAA AAG GCT and TGG AAC TGA AGT ATT GGA AAA CCA); *TMPRSS2* promoter (CTG AGC CCC CAC AAT TGC AAA AC and GGT GGG ACA CAC CTC AGC C); *RBL1* promoter (CAG CGT GGG GCT TGT CCT CG and AGC GGA GGC AGA CGG TGG AT)^[@R9]^; *MyoD1* enhancer (CAG CCA AGT ATC CTC CTC CA and AAG CTG AGC ACT CTG GGA GA)^[@R14]^; *FASN* enhancer (CTA CTT CTC CCG TGC CAC TC and TCT CTC CCC TTC GAT GTG TC); and *NDRG1* enhancer (GGT CAC ATC CAA GTG GGA CT and AGA AGG TGG AGA GGG CAG TT).

### PCR primer for *PSA* Enhancer {#S30}

(ATA GGG TTG GGC ACT CAC AGC TGA AT and AAT GCT GGC AGA GTC CAT GAG ACT CC).

### RT-PCR primer for AR variants {#S31}

The full-length and truncated ARs were detected using primers as described^[@R12]^. F1: TGT CAC TAT GGA GCT CTC ACA TGT GG; R1: CAC CTC TCA AAT ATG CTA GAC GAA TCT GT; R2: GTA CTC ATT CAA GTA TCA GAT ATG CGG TAT CAT; F6: CCA TCT TGT CGT CTT CGG AAA TGT TAT GAA GC; R8: AGC TTC TGG GTT GTC TCC TCA GTG G
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![Signal-Dependent Interaction between AR and Prostate Specific LncRNAs\
**a** and **b**, RIP assay performed in paired benign prostatic hyperplasia (BPH) and prostate tumor (T) tissues. **c**, RIP assay in DHT-treated LNCaP cells (100 nM) for indicated time points. **d**, RIP assay in LNCaP cells transfected with indicated ASO followed by DHT treatment (100 nM). **e**, Global changes in DHT-induced AR target genes in *PCGEM1* or *PRNCR1* depleted LNCaP cells. **f**, Heatmap showing the distribution of *PCGEM1* and AR binding sites in DHT-stimulated LNCaP cells. **g**, Average tag profile analysis of the aligned 2,142 *PCGEM1* ChIRP peaks. Mean ± SEM for panel c and e (*n*=3).](nihms-505618-f0001){#F1}

![Mechanistic Study of LncRNA with Associated Transcription Factors/Co-activators\
**a** and **b**, RIP assay in DHT-treated LNCaP cells (100 nM) expressing indicated plasmids. **c**. *In vitro* methylation assay for AR. **d** and **e**, LNCaP cells expressing Myc-tagged AR fragments (d) or co-transfect with Flag-tagged DOT1L (e) were subjected to RNA pulldown assay. **f**, *In vitro* transcribed *PCGEM1* full-length, Δ411-490, or Δ1191-1270 were incubated with cell lysates extracted from DHT-treated LNCaP cell (100 nM, 1 hr) for *in vitro* RNA pulldown assay. Mean ± SEM for panel a and b (*n*=3).](nihms-505618-f0002){#F2}

![*PCGEM1* and *PRNCR1* Promote Hormone-independent Activation of the AR Transcriptional Program in Castration Resistant Prostate Cancer (CRPC)\
**a**, qRT-PCR analyses of AR targets in LNCaP cells co-transfected with indicated vectors followed by Doxycycline induction (160 ng/ml, 2d). **b**, RIP assay in CWR22Rv1 cells treated with or without DHT (100 nM, 1hr) using indicated antibodies. Detection of immunoprecipitated full-length AR and AR-V7 were shown. **c**, Cell proliferation assay in CWR22Rv1 cells stably expressing indicated shRNAs followed by Doxycycline induction (160 ng/ml) for indicated times. **d**, Xenografts of CWR22Rv1 cell lines harboring Doxycycline-induced shRNAs were monitored for tumor growth for the indicated time, with or without Doxycycline intake (4 mice/group). Mean ± SEM (*n*=6, \**p*\<0.05 and \*\**p*\<0.01).](nihms-505618-f0003){#F3}

![Regulation of Enhancer: Promoter Interaction by *PRNCR1* and *PCGEM1*\
**a**, ChIP-3C in LNCaP cells with indicated ASO transfection and treatment. **b**, ChIP--qPCR showing Pygo2 occupancy in DHT-treated LNCaP cells (100 nM) at indicated times. **c**, ChIP-qPCR indicate the Pygo2 recruitment in LNCaP cells with indicated transfection and treatment. **d**, ChIP-3C in LNCaP cells with indicated siRNA transfection and treatment. **e**, Global changes in DHT-induced AR targets in LNCaP cells with indicated siRNA transfection and treatment. **f**, 3C assay on *FASN* locus in LNCaP-cds2 cells transduced with indicated shRNA harboring lentivirus. Red box indicate PCR product sequenced in a and f. Mean ± SEM (*n*=3, \**p*\<0.05 and \*\**p*\<0.01).](nihms-505618-f0004){#F4}
